The Global Optic Neuritis Treatment Market was valued at US$ 204.9 million in 2022. It is expected to grow to US$ 302.7 million by 2030, with a compound annual growth rate (CAGR) of about 5% during the forecast period from 2023 to 2030.

This growth is driven by the rising incidence of multiple sclerosis and other autoimmune disorders that lead to optic neuritis. Improvements in treatment options, such as steroid and immunomodulator therapies, along with better diagnostic capabilities, are also factors. Moreover, increasing awareness and the adoption of new therapies, along with expanding healthcare infrastructure, support this market growth.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/optic-neuritis-treatment-market?ram

Key Developments:

United States: Optic Neuritis Treatment

- October 2025: Biogen and Novartis moved forward with clinical trials for monoclonal antibody therapies targeting the autoimmune mechanisms behind optic neuritis. They aim to improve effectiveness and reduce relapse rates.

- September 2025: Roche expanded its role in neuro-ophthalmology by launching a biosimilar corticosteroid, approved for treating optic neuritis, which offers more convenient administration.

- August 2025: GenSight Biologics and Santhera Pharmaceuticals partnered to develop gene therapies and neuroprotective agents that address inflammation and degeneration of the optic nerve.

- July 2025: Teva Pharmaceutical Industries introduced personalized treatment platforms that integrate advanced imaging diagnostics like optical coherence tomography (OCT) to customize optic neuritis management.

Japan: Optic Neuritis Treatment

- October 2025: Santen Pharmaceutical Co., Ltd. and Eisai Co., Ltd. launched pilot programs that combine immunomodulatory drugs with digital monitoring of patients to improve treatment outcomes.

- September 2025: Astellas Pharma partnered with local hospitals to study novel oral therapies that reduce inflammation in the optic nerve.

- August 2025: Chugai Pharmaceutical Co., Ltd. created new corticosteroid formulations designed to lessen side effects and improve patient adherence in optic neuritis treatment.

- July 2025: Research collaborations among universities and companies in Japan focused on AI-driven diagnostic tools to enable earlier detection and intervention.

Recent Mergers and Acquisitions (M&A):

United States: Optic Neuritis Treatment

- October 2025: GenSight Biologics acquired a neuro-therapeutics startup that specializes in gene editing technologies for optic nerve disorders.

- August 2025: Novartis formed strategic alliances with biotech companies to speed up the development of targeted monoclonal antibodies for autoimmune optic neuritis.

Japan: Optic Neuritis Treatment

- October 2025: Santen Pharmaceutical merged with a regional specialty pharma firm to enhance its neuro-ophthalmology portfolio, particularly in therapies for optic neuritis.

- August 2025: Eisai Co., Ltd. entered a joint venture with a digital health company to integrate telemedicine into optic neuritis treatment plans.

Key Players:

Mallinckrodt Pharmaceuticals, Teijin Pharmaceutical Limited, AbbVie (Allergan PLC), AdvaCare Pharma, Novartis AG, Trethera Corporation, Santen Pharmaceuticals Corp, Teva Pharmaceutical Industries Ltd, Genentech, Inc., and Alexion Pharmaceuticals, Inc.

Market Dynamics and Growth Drivers:

- Growing Incidence of Optic Neuritis & Associated Diseases: The increase in conditions like Multiple Sclerosis (MS) and other demyelinating disorders often linked with optic neuritis boosts the need for effective treatments. Many optic neuritis cases result from autoimmune attacks on the optic nerve.

- Advancements in Therapeutic Approaches: Innovations in treatment methods are developing beyond standard corticosteroids. These include immunomodulatory agents, neuroprotective treatments, and therapies aimed at repairing the optic nerve, which can potentially improve long-term results.

- Increased Awareness & Diagnostic Capability: Better diagnostic tools, such as MRI and optical coherence tomography, along with growing awareness among healthcare providers and patients, help ensure earlier intervention, which is vital for preserving vision.

- Healthcare Infrastructure Expansion in Emerging Markets: Increased healthcare investment, better access to neurological and ophthalmological care, and growing hospital and clinic capacities in emerging markets contribute to market growth.

- Aging Population and Chronic Disease Burden: The global population is aging, and there is a growing incidence of chronic conditions, like autoimmune diseases and infections, that could lead to optic neuritis. This expands the need for treatment options.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=optic-neuritis-treatment-market?ram

Growth Forecast Projected:

The Global Optic Neuritis Treatment Market is expected to grow at a significant pace from 2024 to 2031. In 2023, the market is already experiencing steady growth. With an increase in the adoption of strategies by key players, growth is anticipated to continue in the coming years.

Research Process:

The research report on the Global Optic Neuritis Treatment Market relies on both primary and secondary data sources. The research process examines factors affecting the industry, including government regulations, market conditions, competitive levels, historical data, technological advancements, and emerging developments in related sectors. It also assesses market volatility, prospects, potential barriers, and challenges.

Key Segments:

- By Type: Idiopathic Optic Neuritis, Multiple Sclerosis-Related Optic Neuritis, Neuromyelitis Optica (NMO), Toxic Optic Neuropathy, Others

- By Treatment: Steroidal Therapy, Immunomodulators Therapy, Other Treatments

- By End User: Hospitals, Clinics, Ambulatory Surgical Centers, Others

Contact Us -

Company Name: DataM Intelligence

Contact Person: Sai Kiran

Email: Sai.k@datamintelligence.com

Phone: +1 877 441 4866

Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.